Market Research Life Sciences Market Research Biotechnology Market Research Antibody Technologies Market Research

Protein Therapeutics Market (Product: Monoclonal Antibodies, Enzyme Replacement Therapy, Cytokines, Fusion Proteins, Anti-coagulants, Bone Morphogenetic Proteins (BMPs), Hormones, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Fo

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 185 Pages Transparency Market Research Pvt. Ltd. January, 2024 TNPR18580356
Best Price Guarantee
Price from $5,795
Length 185 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date January, 2024
SKU TNPR18580356

Protein Therapeutics Market (Product: Monoclonal Antibodies, Enzyme Replacement Therapy, Cytokines, Fusion Proteins, Anti-coagulants, Bone Morphogenetic Proteins (BMPs), Hormones, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Protein Therapeutics Market – Scope of Report

TMR’s report on the global protein therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global protein therapeutics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global protein therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the protein therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global protein therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global protein therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global protein therapeutics market.

The report delves into the competitive landscape of the global protein therapeutics market. Key players operating in the global protein therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global protein therapeutics market profiled in this report.

Key Questions Answered in Global protein therapeutics Market Report
  • What is the sales/revenue generated by protein therapeutics across all regions during the forecast period?
  • What are the opportunities in the global protein therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Protein Therapeutics Market – Research Objectives and Research Approach

The comprehensive report on the global protein therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global protein therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global protein therapeutics market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Protein Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Protein Therapeutics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Therapeutic monoclonal antibodies approved or in review in the EU or US.
5.2. Regulatory Scenario
5.3. Key Products or Brand Analysis
5.4. Technological Advances in Protein Therapeutics.
5.5. Engineering protein-based therapeutics through structural and chemical design
6. Global Protein Therapeutics Market Analysis and Forecast, By Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.2. Enzyme Replacement Therapy
6.3.3. Cytokines
6.3.3.1. Interferons
6.3.3.2. Interleukins
6.3.3.3. Growth Factors
6.3.4. Fusion Proteins
6.3.5. Anti-coagulants
6.3.6. Bone Morphogenetic Proteins (BMPs)
6.3.7. Hormones
6.3.8. Others (engineered protein scaffolds, etc.)
6.4. Market Attractiveness Analysis, By Product
7. Global Protein Therapeutics Market Analysis and Forecast, By Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Metabolic Disorders
7.3.2. Immunologic Disorders
7.3.3. Hematological Disorders
7.3.4. Cancer
7.3.5. Genetic Disorders
7.4. Market Attractiveness Analysis, By Application
8. Global Protein Therapeutics Market Analysis and Forecast, By Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Injectable Proteins
8.3.2. Oral Proteins
8.4. Market Attractiveness Analysis, By Route of Administration
9. Global Protein Therapeutics Market Analysis and Forecast, By Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, By Region
10. North America Protein Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2017–2031
10.2.1. Monoclonal Antibodies
10.2.2. Enzyme Replacement Therapy
10.2.3. Cytokines
10.2.3.1. Interferons
10.2.3.2. Interleukins
10.2.3.3. Growth Factors
10.2.4. Fusion Proteins
10.2.5. Anti-coagulants
10.2.6. Bone Morphogenetic Proteins (BMPs)
10.2.7. Hormones
10.2.8. Others (engineered protein scaffolds, etc.)
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Metabolic Disorders
10.3.2. Immunologic Disorders
10.3.3. Hematological Disorders
10.3.4. Cancer
10.3.5. Genetic Disorders
10.4. Market Value Forecast, by Route of Administration, 2017–2031
10.4.1. Injectable Proteins
10.4.2. Oral Proteins
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By Route of Administration
10.6.4. By Country
11. Europe Protein Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Monoclonal Antibodies
11.2.2. Enzyme Replacement Therapy
11.2.3. Cytokines
11.2.3.1. Interferons
11.2.3.2. Interleukins
11.2.3.3. Growth Factors
11.2.4. Fusion Proteins
11.2.5. Anti-coagulants
11.2.6. Bone Morphogenetic Proteins (BMPs)
11.2.7. Hormones
11.2.8. Others (engineered protein scaffolds, etc.)
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Metabolic Disorders
11.3.2. Immunologic Disorders
11.3.3. Hematological Disorders
11.3.4. Cancer
11.3.5. Genetic Disorders
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Injectable Proteins
11.4.2. Oral Proteins
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Application
11.6.3. By Route of Administration
11.6.4. By Country/Sub-region
12. Asia Pacific Protein Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Monoclonal Antibodies
12.2.2. Enzyme Replacement Therapy
12.2.3. Cytokines
12.2.3.1. Interferons
12.2.3.2. Interleukins
12.2.3.3. Growth Factors
12.2.4. Fusion Proteins
12.2.5. Anti-coagulants
12.2.6. Bone Morphogenetic Proteins (BMPs)
12.2.7. Hormones
12.2.8. Others (engineered protein scaffolds, etc.)
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Metabolic Disorders
12.3.2. Immunologic Disorders
12.3.3. Hematological Disorders
12.3.4. Cancer
12.3.5. Genetic Disorders
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Injectable Proteins
12.4.2. Oral Proteins
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By Route of Administration
12.6.4. By Country/Sub-region
13. Latin America Protein Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Monoclonal Antibodies
13.2.2. Enzyme Replacement Therapy
13.2.3. Cytokines
13.2.3.1. Interferons
13.2.3.2. Interleukins
13.2.3.3. Growth Factors
13.2.4. Fusion Proteins
13.2.5. Anti-coagulants
13.2.6. Bone Morphogenetic Proteins (BMPs)
13.2.7. Hormones
13.2.8. Others (engineered protein scaffolds, etc.)
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Metabolic Disorders
13.3.2. Immunologic Disorders
13.3.3. Hematological Disorders
13.3.4. Cancer
13.3.5. Genetic Disorders
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Injectable Proteins
13.4.2. Oral Proteins
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By Route of Administration
13.6.4. By Country/Sub-region
14. Middle East & Africa Protein Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2031
14.2.1. Monoclonal Antibodies
14.2.2. Enzyme Replacement Therapy
14.2.3. Cytokines
14.2.3.1. Interferons
14.2.3.2. Interleukins
14.2.3.3. Growth Factors
14.2.4. Fusion Proteins
14.2.5. Anti-coagulants
14.2.6. Bone Morphogenetic Proteins (BMPs)
14.2.7. Hormones
14.2.8. Others (engineered protein scaffolds, etc.)
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Metabolic Disorders
14.3.2. Immunologic Disorders
14.3.3. Hematological Disorders
14.3.4. Cancer
14.3.5. Genetic Disorders
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Injectable Proteins
14.4.2. Oral Proteins
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Application
14.6.3. By Route of Administration
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2022)
15.3. Company Profiles
15.3.1. Thermo Fisher Scientific, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Material Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Genzyme Corporation (Sanofi)
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Material Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. AbbVie, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Material Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Sanofi
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Material Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Leadiant Biosciences
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Material Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Takeda Pharmaceutical Company Limited
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Material Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Amicus Therapeutics
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Material Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Bayer AG
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Material Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Bristol-Myers Squibb
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Material Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. DAIICHI SANKYO COMPANY
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Material Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Abbott
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Material Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Sanofi
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Material Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings